Otonomy drug flunks Phase IIb: full speed ahead to Phase III
This article was originally published in Scrip
Executive Summary
Otonomy saw its share price plummet by nearly 18% in after-hours trading on 21 May after it announced that its investigational treatment OTO-104 for Ménière's disease had failed a Phase IIb trial. That a range of secondary endpoints were met and the company's decision to move it into Phase III based on the data evidently failed to settle investors' nerves.
You may also be interested in...
Otonomy’s Otividex Fails Again In Phase III Meniere’s Study
Otividex did not significantly reduce vertigo three months after treatment, so Otonomy appears to be moving on from Meniere’s disease and focusing on earlier-stage tinnitus and hearing loss candidates.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.